Prostate Cancer: Clinical Trials & Research

Michael Morris Michael Morris and other medical oncologists at Memorial Sloan Kettering lead clinical trials of new drugs for the treatment of metastatic prostate cancer.

One of the reasons we know so much about prostate cancer and how best to treat it is that our researchers are among the world’s most skilled — and determined. More than 100 of our clinical scientists and laboratory investigators study the basic biology of prostate cancer to hunt for even better ways to detect it, treat it, and ensure it doesn’t come back, in both the men we care for and all the ones we don’t. We’re constantly looking for tools to more precisely detect prostate cancer, guide our decisions about therapy, monitor response to treatment, and track the progression of cancer over time. Among other approaches, we’re investigating new ways to diagnose and treat prostate cancer, using things like:

  • imaging techniques
  • immunotherapies that harness the power of the immune system to eliminate cancer cells
  • molecular diagnostics that characterize the aggressiveness of a cancer and help determine the best way to kill it

Biomarkers are another area of intensive research at MSK. These biological molecules can provide a clear indication of disease, and we’re increasingly using them in our arsenal of molecular tests for prostate cancer. For example, our physician-scientists are studying the use of an advanced molecular test for PCA3 (prostate cancer antigen 3) using urine. PCA3 is a gene that is specific to prostate cancer — it’s expressed in more than 90 percent of prostate cancer tissue but not in normal prostate tissue — and a simple urine sample can show if the gene is in your urine. For men with advanced disease, we’re examining the effectiveness of a blood test that may be capable of detecting a single prostate cancer cell among a billion or more healthy cells. Interest in these cells, called circulating tumor cells, has increased with the availability of new technologies to detect, count, and characterize them. This new “liquid biopsy” may offer a noninvasive, highly accurate way to find cancer cells that cannot easily be detected with current methods.

For men with advanced disease, we’re examining the effectiveness of a blood test that may be capable of detecting a single prostate cancer cell among a billion or more healthy cells. Interest in these cells, called circulating tumor cells, has increased with the availability of new technologies to detect, count, and characterize them. This new “liquid biopsy” may offer a noninvasive, highly accurate way to find cancer cells that cannot easily be detected with current methods.

Prostate Cancer Clinical Trials

Our busy research program means that we’re often able to offer men at all clinical states of prostate cancer access to clinical trials of new treatments, sometimes years before they’re widely available. These trials test new drugs and drug combinations, surgical and radiation therapy techniques, innovative diagnostic technologies, and strategies for preserving quality of life for men undergoing treatment. Our experts can help determine which clinical trials are right for you. The following prostate cancer clinical trials at Memorial Sloan Kettering are currently enrolling new patients. To learn more about a study, choose from the list below.

Showing 44 trials
Title Investigatorsort icon
Care for the Cancer Caregiver: A Meaning-Based Workshop to Help Manage Caregiver Burden
Newly Diagnosed & Relapsed/Refractory
[Protocol 14-208]
Applebaum, Allison, PhD
A Phase II Study of Degarelix plus Ipilimumab with Radical Prostatectomy in Men Newly Diagnosed with Metastatic Prostate Cancer
[Protocol 13-134]
Autio, Karen, MD
A Phase I Study of the Immune Activity and Safety of IMC-CS4 in Patients with Advanced Breast or Prostate Cancers
[Protocol 14-204]
Autio, Karen, MD
A Phase I Study of AM0010 in Patients with Advanced Solid Tumors
[Protocol 13-224]
Autio, Karen, MD
Surviving Oropharynx Cancer: Long-Term Impact of Human Papillomavirus on Quality of Life
[Protocol 10-111]
Baxi, Shrujal, MD
Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life
[Protocol 10-071]
Blinder, Victoria, MD
A Study of an Online Support Group for Women Experiencing Sexual Distress due to a Gynecologic Cancer
[Protocol 14-245]
Carter, Jeanne, PhD
Acupuncture for Chronic Lymphedema After Breast Cancer Treatment
[Protocol 12-210]
Cassileth, Barrie, PhD
A Phase I Study of DSTP3086S in Patients with Metastatic Castration-Resistant Prostate Cancer
[Protocol 11-016]
Danila, Daniel, MD
A Phase I/II Study of Ipilimumab Given with Abiraterone and Prednisone in Men with Metastatic Castration-Resistant Prostate Cancer
[Protocol 12-120]
Danila, Daniel, MD
A Phase II Study of MLN8237 in Patients with Advanced Prostate Cancer
[Protocol 13-042]
Danila, Daniel, MD
A Phase III Study of Armodafinil versus Placebo to Reduce Cancer-Related Fatigue in Patients with High-Grade Glioma
Newly Diagnosed & Relapsed/Refractory
[Protocol 14-040]
Diamond, Eli, MD
Prognostic Awareness and Patient-Physician Communication in Malignant Glioma
[Protocol 13-253]
Diamond, Eli, MD
A Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
[Protocol 07-041]
Eastham, James, MD
A Study of Physician Communication Skills to Promote Patients' Transition to Survivorship
[Protocol 11-180]
Horwitz, Steven, MD
A Study Assessing the Safety and Tolerability of Supervised Aerobic Exercise Training in Women with Metastatic Breast Cancer
[Protocol 14-170]
Jones, Lee, PhD
A Study Assessing the Influence of Breast MRI Before Lumpectomy on Outcomes, Quality of Life, and Costs in Women with Breast Cancer
Newly Diagnosed
[Protocol 14-198]
King, Tari, MD
A Study Assessing the Safety and Effectiveness of Ultra-Hypofractionated Radiation Therapy after Brachytherapy for Localized Intermediate-Risk Prostate Cancer
Newly Diagnosed
[Protocol 14-193]
Kollmeier, Marisa, MD
A Study Assessing the Use of Dual Handset Phones to Improve Communication with Inpatients Who Have Limited English Proficiency
[Protocol 14-042]
Kumar, Chhavi, MD
Quality of Life Assessment in Breast Cancer Patients with Radiation-Induced Telangiectasias Treated with Pulsed Dye Laser
[Protocol 13-013]
Lee, Erica, MD
Evaluation of Physical Function and Quality of Life Before and After Non-Radical Surgery for Stage I Cervical Cancer
Newly Diagnosed
[Protocol 13-210]
Leitao, Mario, MD
Development of Psychotherapeutic Interventions for Parents Who Lost a Child to Cancer
[Protocol 14-102]
Lichtenthal, Wendy, PhD
A Phase III Study of Enzalutamide Alone or with Abiraterone and Prednisone for Metastatic Castration-Resistant Prostate Cancer
[Protocol 13-247]
Morris, Michael, MD
[18F]-Deoxy-D-Glucose (FDG) and [18F] Dihydro-Testosterone PET Imaging in Patients with Progressive Prostate Cancer
[Protocol 00-095]
Morris, Michael, MD
A Phase II Study of Abiraterone Acetate without Simultaneous Prednisone in Men with Castration-Resistant Prostate Cancer, with Hormonal Assessment During Treatment
[Protocol 14-188]
Morris, Michael, MD
Identifying and Measuring Depression in Older People with Cancer
[Protocol 14-101]
Nelson, Christian, PhD
The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men with Prostate Cancer Age 65 and Older
[Protocol 06-084]
Nelson, Christian, PhD
Decision-Making about Active Surveillance among Prostate Cancer Patients and Their Partners/Allies
[Protocol 13-076]
Nelson, Christian, PhD
Clinical Significance of Germline BRCA Mutations
[Protocol 96-051]
Offit, Kenneth, MD
A Study of [18F] Dihydro-testosterone PET and MR Imaging in Patients with Localized Prostate Cancer
Newly Diagnosed & Relapsed/Refractory
[Protocol 14-185]
Osborne, Joseph, MD, PhD
A Phase III Study of ARN-509 versus Placebo in Men with Non-Metastatic Castration-Resistant Prostate Cancer
[Protocol 13-243]
Rathkopf, Dana, MD
A Phase II Study of MLN0128 in Men with Castration-Resistant Prostate Cancer
[Protocol 13-143]
Rathkopf, Dana, MD
A Phase Ib Study of ARN-509 plus Everolimus in Men with Progressive Metastatic Castration-Resistant Prostate Cancer After Abiraterone Therapy
[Protocol 13-025]
Rathkopf, Dana, MD
A Study of Degarelix Before Prostatectomy in Patients with Intermediate- to High-Risk Prostate Cancer
[Protocol 11-182]
Rathkopf, Dana, MD
A Phase IA/B Study of CC-115 in Castration-Resistant Prostate Cancer
[Protocol 12-080]
Rathkopf, Dana, MD
An Online Testing Approach to Assess Cognitive Problems Associated with Cancer or Its Treatment
Newly Diagnosed & Relapsed/Refractory
[Protocol 14-271]
Root, James, PhD
A Pilot Study of a Geriatric-Specific Psychoeducational Intervention for Elderly Cancer Patients
[Protocol 09-116]
Roth, Andrew, MD
A Phase II Study of Abiraterone, Prednisone, and Degarelix in Men with Recurrent Prostate Cancer and a Rising PSA
[Protocol 12-187]
Scher, Howard, MD
A Phase IV Study of Enzalutamide in Men with Metastatic Prostate Cancer Who Are at Risk for Seizures
[Protocol 13-231]
Slovin, Susan, MD, PhD
A Phase II Study of Abiraterone with or without Cabazitaxel in Patients with Metastatic Castration-Resistance Prostate Cancer
[Protocol 14-046]
Slovin, Susan, MD, PhD
Adoptive Transfer of Autologous T Cells Targeted to Prostate-Specific Membrane Antigen for the Treatment of Metastatic Castration-Resistant Prostate Cancer
[Protocol 09-036]
Slovin, Susan, MD, PhD
The Prevention of Delirium and Complications Associated with Surgical Treatments (PODCAST) Clinical Trial
Newly Diagnosed & Relapsed/Refractory
[Protocol 13-240]
Veselis, Robert, MD
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
[Protocol 11-112]
Zaider, Talia, PhD
A Phase II Study Assessing Contrast-Enhanced MRI to Evaluate Response to Radiation Treatment for Prostate Cancer
Newly Diagnosed & Relapsed/Refractory
[Protocol 14-172]
Zelefsky, Michael, MD